title: Clinical management of ESBL-producing Enterobacteriaceae: the insidious role of fluoroquinolones.
abstract: During a review of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae in our Hospital, a huge number of inadequate antimicrobial therapies emerged. The aim of this study is to assess the factors related to such inadequacy. This retrospective analysis was performed on isolates reported by the microbiology laboratory. Medical records were analyzed to assess adequate treatment; inadequacy was evaluated as overall therapy, antibiotic choice, dosage and length of treatment. Linear regression and multivariate analysis were performed to assess any association. One hundred and fifty isolates were analyzed. They were more commonly isolated from urinary samples and from patients admitted to the Internal Medicine Department; E. coli was the most commonly isolated pathogen. The rate of inadequacy was 60.67%. Fluoroquinolones seem to be the main class responsible. Ceftriaxone, teicoplanin, tigecycline and amoxicillin-clavulanate are other antibiotics inadequately prescribed. Clinical management of these infections should be better tailored: the knowledge of pathogens should be implemented and the use of diagnostic tools, such as microbiology results, must be optimized. In particular, the prescription of each antibiotic course (and above all of regimens containing fluoroquinolones) should be performed not on a routine basis, but after careful assessment of each case.
authors.affiliation: Department of Infectious Diseases and Tropical Medicine, Alessandro Manzoni Hospital, Lecco, Italy. roberto.rossotti@ospedaleniguarda.it
authors.forename: R
authors.initials: R
authors.lastname: Rossotti
authors.forename: A
authors.initials: A
authors.lastname: Orani
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004358:Drug Therapy / Q000379:methods; D004755:Enterobacteriaceae / Q000201:enzymology* / Q000302:isolation & purification; D004756:Enterobacteriaceae Infections / Q000188:drug therapy* / Q000382:microbiology*; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage*; D006302:Health Services Research; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D001618:beta-Lactamases / Q000378:metabolism*
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D001618:beta-Lactamases
references.citation: J Glob Infect Dis. 2009 Jul;1(2):87-92
references.pmid: 20300397
references.citation: Antimicrob Agents Chemother. 2007 Jun;51(6):1987-94
references.pmid: 17387156
references.citation: Antimicrob Agents Chemother. 2002 Mar;46(3):630-7
references.pmid: 11850241
references.citation: J Clin Microbiol. 2006 May;44(5):1659-64
references.pmid: 16672390
references.citation: Clin Infect Dis. 2001 Apr 15;32(8):1162-71
references.pmid: 11283805
references.citation: Antimicrob Agents Chemother. 2008 Sep;52(9):3244-52
references.pmid: 18591273
references.citation: Chemotherapy. 2009;55(4):293-7
references.pmid: 19521075
references.citation: Antimicrob Agents Chemother. 2003 Feb;47(2):559-62
references.pmid: 12543659
references.citation: Infection. 1983 Nov-Dec;11(6):315-7
references.pmid: 6321357
references.citation: Antimicrob Agents Chemother. 1994 Apr;38(4):761-6
references.pmid: 8031043
references.citation: Antimicrob Agents Chemother. 2005 Jan;49(1):71-6
references.pmid: 15616277
references.citation: Clin Infect Dis. 2001 Oct 15;33(8):1288-94
references.pmid: 11565067
references.citation: Euro Surveill. 2008 Nov 20;13(47):
references.pmid: 19021958
references.citation: Arch Intern Med. 2005 Jun 27;165(12):1375-80
references.pmid: 15983286
references.citation: J Clin Microbiol. 2010 Apr;48(4):1019-25
references.pmid: 20181902
references.citation: Antimicrob Agents Chemother. 2010 Oct;54(10):4085-91
references.pmid: 20660675
references.citation: Clin Microbiol Rev. 1995 Oct;8(4):557-84
references.pmid: 8665470